Kura Oncology weekly recap highlights KOMZIFTI and darlifarnib programs

Kura Oncology said KOMZIFTI has emerged as a leading treatment for relapsed/refractory NPM1-mutant AML, with rollout set to expand as it moves toward frontline use. The company also noted darlifarnib and kidney/pancreatic programs are advancing.